ABILITYPHARMA
AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer
PIPELINE
ABTL0812, first-in-class, is currently in phase 2b clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The product has also completed with positive results a phase 2a trial in endometrial cancer and lung cancer in Spain and France. 
SCIENCE
AbilityPharma investigates cancer drugs inducing cytotoxic autophagy selectively in cancer cells

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cell death selectively in cancer cells. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.

Media Center

09.09.2024

Press Release

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024

Press Release

AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
29.12.2020

In the media

The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
29.12.2020

In the media

The Chinese SciClone enters at the biotech Ability Pharma + info

Events

September 13-17 . ESMO Congress Barcelona + info

Events

June 3-6 BIO . San Diego (USA) + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG
This website uses both its own and third-party cookies to compile statistical information about your browsing and to show you publicity related to your preferences, generated on the basis of your browsing patterns. It is assumed that you accept their use if you continue browsing.
AcceptMore information